肿瘤抗体治疗的现状与发展趋势  

Current state and development tendency of tumor therapeutic antibody

作　　者：徐增辉[1] 钱其军[1] 

机构地区：[1]中国人民解放军第二军医大学东方肝胆外科医院基因与病毒治疗实验室,上海200438

出　　处：《临床肝胆病杂志》2011年第4期351-356,共6页Journal of Clinical Hepatology

基　　金：国家杰出青年科学基金(30925037);上海市优秀学科带头人A计划(10XD1406500)

摘　　要：单克隆抗体在过去的30多年里经历了快速的发展,从杂交瘤技术的建立起,科学家先后研发出鼠源性、嵌合型、人源化以及全人化抗体技术。目前FDA批准上市的30个抗体中有10个用于肿瘤治疗,抗体治疗也被认为是肿瘤治疗最有效的方法之一。抗体偶联小分子、化疗药物等也成为人们的研究重点,他们展现出比单个治疗更为有效的临床反应。然而,肿瘤治疗抗体仍然存在着体内半衰期短、杀伤作用不够、难以渗透实体瘤、治疗靶点少、治疗成本高等问题。未来抗体研究的重点将是研制低免疫原性、高亲和性、多效价多克隆、更稳定和低成本的抗体。Monoclonal antibody had achieved huge development in the past thirty years,ranging from hybridoma technology to mouse-derived,mouse/human chimeric,humanized and fully human antibody production technology.So far,thirty monoclonal antibodies have been proved by FDA including ten tumor therapeutic antibodies,and monoclonal antibody has been recognized as one of the most potent therapeutic drugs for tumor.Antibody-drugs conjugated with small molecule,chemotherapeutic drug and so on,which are demonstrated to be more efficient than single drug,have also been the hot spot of antibody research.However,current tumor therapeutic antibodies still have drawbacks including short half-life,unsatisfactory therapeutic potency,solid tumor penetrating difficulty,seldom therapeutic targets and high producing costs to overcome.Future antibody research would focus on these kind of antibodies with lower immunogenicity,higher affinity,multivalent or polyclonal,longer duration and lower costs

关 键 词：抗体 肿瘤 

分 类 号：R730.5[医药卫生—肿瘤]